Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema.

Alazher University Dean

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05464953

Enrollment

Registered

2022-07-19

Start date

2020-01-20

Completion date

2022-04-30

Last updated

2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema of Left Eye

Brief summary

Background Retinal vascular disorders, such as diabetic retinopathy, hypertensive retinopathy, retinal hemorrhage, and retinal vein occlusion are significant causes of vision impairment and blindness worldwide. Diabetic retinopathy (DR) is the most common retinal vascular disorder and is the leading cause of vision loss among patients aged 25 to 74 years. Aim to compare formulated Posterior Subtenon Triamcinolone acetonide (PSTA) injection versus Posterior Subtenon Triamcinolone acetonide alone versus suprachoroidal triamcinolone in the management of diabetic macular edema.

Interventions

DRUGTriamcinolone Acetonide

Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema

DRUGFormulated Triamcinolone

Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 69 Years

Healthy volunteers

Inclusion criteria

* Diminution of vision due to diabetic macular edema. * CMT ≥ 250 µ. * Willing to participate in the study.

Exclusion criteria

* Unwilling to participate in the study, 2) * Ischemic RVO, * previous laser treatment * Glaucoma, macular ischemia, cataract, vitreous hemorrhage, and neovascularization of the iris, * patients with previous anti VEGFs or steroid injections or any eye surgery three months before the inclusion, * Cardiac co-morbidities result in significant hemodynamic changes, 7)Respiratory diseases need treatment with antibiotics, * Suffering from other chronic diseases as diabetes, * Patient with allergy from triamcinolone acetonide.

Design outcomes

Primary

Measure	Time frame	Description
BCVA	Base line	Best-corrected visual acuity
CMT	at baseline	CENTRAL MACULAR THICKNESS

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026